Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, and TRIUMF, Canada's particle accelerator center, recently announced that the companies have entered into the next phase of their collaboration agreement for the development, production, and supply of actinium-225. Fusion will provide to TRIUMF funding to further develop technology to produce actinium-225 and in return Fusion will have rights, including preferred access and pricing, to the resulting alpha-emitting medical isotope.
In
December 2020, Fusion and TRIUMF entered a collaboration and supply agreement
to develop, produce and procure the supply of actinium-225 to Fusion. As part
of this agreement, Fusion will continue its investment of up to $25 million
(CAD) in TRIUMF to advance technology and processes for actinium-225
production.
To
read more please visit:
Source: CISION